Induction of melanoma cell apoptosis and inhibition of tumor growth using a cell-permeable survivin antagonist

H. Yan, J. Thomas, T. Liu, D. Raj, N. London, T. Tandeski, Sancy Leachman, R. M. Lee, D. Grossman

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

The inhibitor of apoptosis gene family member Survivin is highly expressed in most tumors, and appears to be a promising target for cancer therapy. Although a variety of Survivin antagonists have been shown to induce apoptosis in malignant cells, the potential utility of these agents is limited by inefficient delivery and cell impermeability. We generated recombinant fusion proteins containing the TAT protein transduction domain and either wild-type Survivin (TAT-Surv-WT) or a dominant-negative mutant (TAT-Surv-T34A). The TAT-Surv proteins were purified by sequential affinity and ion-exchange chromatography, and at 30nM concentration demonstrated rapid entry into cells at 30min. Whereas TAT-Surv-WT had minimal effect on YUSAC2 or WM793 melanoma cells, TAT-Surv-T34A induced cell detachment, DNA fragmentation, caspase-3 activation and mitochondrial release of apoptosis-inducing factor at low μM concentrations. Intraperitoneal (i.p.) injection of mice bearing subcutaneous YUSAC2 xenografts with TAT-Surv-T34A (10mg/kg) was associated with rapid tumor accumulation at 1h, and increased tumor cell apoptosis and aberrant nuclei formation in situ. Repeated i.p. injection of TAT-Surv-T34A resulted in a 40-50% reduction in growth and mass of established tumors, compared to those similarly injected with saline buffer or TAT-Surv-WT. These studies demonstrate the feasibility of systemic tumor treatment using a cell-permeable Survivin antagonist.

Original languageEnglish (US)
Pages (from-to)6968-6974
Number of pages7
JournalOncogene
Volume25
Issue number52
DOIs
StatePublished - Nov 2 2006
Externally publishedYes

Fingerprint

Melanoma
Apoptosis
Growth
Neoplasms
Intraperitoneal Injections
Apoptosis Inducing Factor
Recombinant Fusion Proteins
Ion Exchange Chromatography
Feasibility Studies
DNA Fragmentation
Inhibition (Psychology)
Heterografts
Caspase 3
Buffers
Therapeutics
Genes
Proteins

Keywords

  • Apoptosis
  • Melanoma
  • Survivin
  • TAT
  • Xenograft

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics

Cite this

Yan, H., Thomas, J., Liu, T., Raj, D., London, N., Tandeski, T., ... Grossman, D. (2006). Induction of melanoma cell apoptosis and inhibition of tumor growth using a cell-permeable survivin antagonist. Oncogene, 25(52), 6968-6974. https://doi.org/10.1038/sj.onc.1209676

Induction of melanoma cell apoptosis and inhibition of tumor growth using a cell-permeable survivin antagonist. / Yan, H.; Thomas, J.; Liu, T.; Raj, D.; London, N.; Tandeski, T.; Leachman, Sancy; Lee, R. M.; Grossman, D.

In: Oncogene, Vol. 25, No. 52, 02.11.2006, p. 6968-6974.

Research output: Contribution to journalArticle

Yan, H, Thomas, J, Liu, T, Raj, D, London, N, Tandeski, T, Leachman, S, Lee, RM & Grossman, D 2006, 'Induction of melanoma cell apoptosis and inhibition of tumor growth using a cell-permeable survivin antagonist', Oncogene, vol. 25, no. 52, pp. 6968-6974. https://doi.org/10.1038/sj.onc.1209676
Yan, H. ; Thomas, J. ; Liu, T. ; Raj, D. ; London, N. ; Tandeski, T. ; Leachman, Sancy ; Lee, R. M. ; Grossman, D. / Induction of melanoma cell apoptosis and inhibition of tumor growth using a cell-permeable survivin antagonist. In: Oncogene. 2006 ; Vol. 25, No. 52. pp. 6968-6974.
@article{90f6c92e7eb54e09bcb7da37e83ffe08,
title = "Induction of melanoma cell apoptosis and inhibition of tumor growth using a cell-permeable survivin antagonist",
abstract = "The inhibitor of apoptosis gene family member Survivin is highly expressed in most tumors, and appears to be a promising target for cancer therapy. Although a variety of Survivin antagonists have been shown to induce apoptosis in malignant cells, the potential utility of these agents is limited by inefficient delivery and cell impermeability. We generated recombinant fusion proteins containing the TAT protein transduction domain and either wild-type Survivin (TAT-Surv-WT) or a dominant-negative mutant (TAT-Surv-T34A). The TAT-Surv proteins were purified by sequential affinity and ion-exchange chromatography, and at 30nM concentration demonstrated rapid entry into cells at 30min. Whereas TAT-Surv-WT had minimal effect on YUSAC2 or WM793 melanoma cells, TAT-Surv-T34A induced cell detachment, DNA fragmentation, caspase-3 activation and mitochondrial release of apoptosis-inducing factor at low μM concentrations. Intraperitoneal (i.p.) injection of mice bearing subcutaneous YUSAC2 xenografts with TAT-Surv-T34A (10mg/kg) was associated with rapid tumor accumulation at 1h, and increased tumor cell apoptosis and aberrant nuclei formation in situ. Repeated i.p. injection of TAT-Surv-T34A resulted in a 40-50{\%} reduction in growth and mass of established tumors, compared to those similarly injected with saline buffer or TAT-Surv-WT. These studies demonstrate the feasibility of systemic tumor treatment using a cell-permeable Survivin antagonist.",
keywords = "Apoptosis, Melanoma, Survivin, TAT, Xenograft",
author = "H. Yan and J. Thomas and T. Liu and D. Raj and N. London and T. Tandeski and Sancy Leachman and Lee, {R. M.} and D. Grossman",
year = "2006",
month = "11",
day = "2",
doi = "10.1038/sj.onc.1209676",
language = "English (US)",
volume = "25",
pages = "6968--6974",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "52",

}

TY - JOUR

T1 - Induction of melanoma cell apoptosis and inhibition of tumor growth using a cell-permeable survivin antagonist

AU - Yan, H.

AU - Thomas, J.

AU - Liu, T.

AU - Raj, D.

AU - London, N.

AU - Tandeski, T.

AU - Leachman, Sancy

AU - Lee, R. M.

AU - Grossman, D.

PY - 2006/11/2

Y1 - 2006/11/2

N2 - The inhibitor of apoptosis gene family member Survivin is highly expressed in most tumors, and appears to be a promising target for cancer therapy. Although a variety of Survivin antagonists have been shown to induce apoptosis in malignant cells, the potential utility of these agents is limited by inefficient delivery and cell impermeability. We generated recombinant fusion proteins containing the TAT protein transduction domain and either wild-type Survivin (TAT-Surv-WT) or a dominant-negative mutant (TAT-Surv-T34A). The TAT-Surv proteins were purified by sequential affinity and ion-exchange chromatography, and at 30nM concentration demonstrated rapid entry into cells at 30min. Whereas TAT-Surv-WT had minimal effect on YUSAC2 or WM793 melanoma cells, TAT-Surv-T34A induced cell detachment, DNA fragmentation, caspase-3 activation and mitochondrial release of apoptosis-inducing factor at low μM concentrations. Intraperitoneal (i.p.) injection of mice bearing subcutaneous YUSAC2 xenografts with TAT-Surv-T34A (10mg/kg) was associated with rapid tumor accumulation at 1h, and increased tumor cell apoptosis and aberrant nuclei formation in situ. Repeated i.p. injection of TAT-Surv-T34A resulted in a 40-50% reduction in growth and mass of established tumors, compared to those similarly injected with saline buffer or TAT-Surv-WT. These studies demonstrate the feasibility of systemic tumor treatment using a cell-permeable Survivin antagonist.

AB - The inhibitor of apoptosis gene family member Survivin is highly expressed in most tumors, and appears to be a promising target for cancer therapy. Although a variety of Survivin antagonists have been shown to induce apoptosis in malignant cells, the potential utility of these agents is limited by inefficient delivery and cell impermeability. We generated recombinant fusion proteins containing the TAT protein transduction domain and either wild-type Survivin (TAT-Surv-WT) or a dominant-negative mutant (TAT-Surv-T34A). The TAT-Surv proteins were purified by sequential affinity and ion-exchange chromatography, and at 30nM concentration demonstrated rapid entry into cells at 30min. Whereas TAT-Surv-WT had minimal effect on YUSAC2 or WM793 melanoma cells, TAT-Surv-T34A induced cell detachment, DNA fragmentation, caspase-3 activation and mitochondrial release of apoptosis-inducing factor at low μM concentrations. Intraperitoneal (i.p.) injection of mice bearing subcutaneous YUSAC2 xenografts with TAT-Surv-T34A (10mg/kg) was associated with rapid tumor accumulation at 1h, and increased tumor cell apoptosis and aberrant nuclei formation in situ. Repeated i.p. injection of TAT-Surv-T34A resulted in a 40-50% reduction in growth and mass of established tumors, compared to those similarly injected with saline buffer or TAT-Surv-WT. These studies demonstrate the feasibility of systemic tumor treatment using a cell-permeable Survivin antagonist.

KW - Apoptosis

KW - Melanoma

KW - Survivin

KW - TAT

KW - Xenograft

UR - http://www.scopus.com/inward/record.url?scp=33750578184&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750578184&partnerID=8YFLogxK

U2 - 10.1038/sj.onc.1209676

DO - 10.1038/sj.onc.1209676

M3 - Article

C2 - 16702945

AN - SCOPUS:33750578184

VL - 25

SP - 6968

EP - 6974

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 52

ER -